Moderna Lifts FY Revenue Growth Outlook to 15%-25% After Q3 Beat
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna posted $162 million of Q3 net income, or $0.38 diluted EPS, on $1.3 billion of revenue, up 29% year over year, and raised its 2026 revenue growth outlook to 15%-25%, with the 2026 revenue forecast now at $2.236-$2.430 billion, above the $2.102 billion analyst estimate. It also now expects year-end cash of $8.1-$8.3 billion. The swing to profit is a sharp turn from the $782 million net loss reported in Q2, when the norovirus vaccine failed a Phase 3 interim look and a $950 million litigation settlement weighed on results. The raised outlook is the key new piece: management is now guiding to faster top-line growth than previously communicated, backed by the flu vaccine approval and COVID booster season. The stock is trading near its 52-week high, so the guidance raise extends a run that began with the August intismeran melanoma data.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Moderna raised its 2026 revenue forecast to $2.236-$2.430 billion, above the $2.102 billion analyst estimate, and now expects year-end cash of $8.1-$8.3 billion.
At the time of this announcement, MRNA was trading at $265.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.